Tebano M T, Traversa G, Da Cas R, Loizzo A
Istituto Superiore di Sanità, Rome, Italy.
Aliment Pharmacol Ther. 1996 Aug;10(4):659-63. doi: 10.1046/j.1365-2036.1996.18160000.x.
Sulphasalazine and 5-amino salicyclic acid drugs are specifically indicated for the treatment of inflammatory bowel disease.
To use drug consumption by a given population as a marker to estimate the number of patients with inflammatory bowel disease.
Prescriptions for sulphasalazine and mesalazine were identified for the 133000 inhabitants of a local health unit in Rome. Other prescriptions received by the patients, who were users of sulphasalazine or mesalazine, were also studied.
99465 patients received at least one prescription for any drug in 1991. Three hundred and seventy-six patients were prescribed sulphasalazine and/or mesalazine, an average of 3.8 prescriptions per patient. These patients were exposed more frequently than the general population to other drugs often used in inflammatory bowel disease treatment, for example, corticosteroids, anti-diarrhoeal drugs and intestinal anti-infectives. We identified that 258 of 100000 inhabitants were prescribed either sulphasalazine or mesalazine; 127 of 100000 inhabitants received full-dose treatment for at least 30 days, and 42.8 of 100000 inhabitants received prescriptions of either drug, also associated with systemic corticosteroids.
The consumption of drugs used specifically for inflammatory bowel disease may act as a marker for the prevalence of the condition in a community.
柳氮磺胺吡啶和5-氨基水杨酸类药物是治疗炎症性肠病的特效药物。
以特定人群的药物消费量为指标，估算炎症性肠病患者的数量。
对罗马当地一个卫生单位的133000名居民的柳氮磺胺吡啶和美沙拉嗪处方进行了统计。同时也研究了使用柳氮磺胺吡啶或美沙拉嗪的患者所开具的其他处方。
1991年，99465名患者至少接受过一种药物的处方。376名患者开具了柳氮磺胺吡啶和/或美沙拉嗪，平均每位患者3.8张处方。这些患者比普通人群更频繁地使用常用于治疗炎症性肠病的其他药物，如皮质类固醇、止泻药和肠道抗感染药。我们发现，每10万居民中有258人开具了柳氮磺胺吡啶或美沙拉嗪；每10万居民中有127人接受了至少30天的全剂量治疗，每10万居民中有42.8人开具了这两种药物之一的处方，且与全身性皮质类固醇有关。
专门用于治疗炎症性肠病的药物消费量可作为社区中该病患病率的一个指标。
